The treatment of liver cirrhosis by transplantation of the hepatic progenitor cells with transformation

转化肝祖细胞移植治疗肝硬化

• 批准号: 23591987
• 负责人: MIZUMOTO MASAKI
• 金额: $ 3.24万
• 依托单位: Kyoto University (2012-2013)Foundation for Biomedical Research and Innovation (2011)
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591987/
• 关键词: 肝線維化; TGFβ; BMP7; 肝硬変; 肝繊維化; 遺伝子導入; プラスミドベクター; 肝再生; 肝細胞移植; 肝不全治療; BMP-7; TGF β

One of the purpose of this study was to evaluate the effectiveness of BMP7. BMP7 is an inhibitor of TGF-beta which is one of the key moleclue of liver cirrhosis. We made BMP7 expressing plasmid vector, and perfomed transfection using a model of liver cirrhosis induced by CCl4.Howerver, the findings of the liver cirrhosis showed by HE staining, Masson Trichrome staining (MT staining), and RT-PCR for collagen 1a gene expression were not different between the group with BMP7 tarnsfection and without BMP7 transfection in the mouse liver cirrhosis model. With these results, we could not show the effectiveness of BMP7 in the treatment of liver cirrhosis.

本研究的目的之一是评估BMP7的有效性。BMP7是一种转化生长因子-β的抑制物，转化生长因子-β是肝硬化的关键分子之一。我们构建了BMP7表达载体，并用CCl4诱导的小鼠肝纤维化模型进行了表达。在小鼠肝纤维化模型中，HE染色、Masson三色染色(MT染色)和RT-PCR检测1a胶原蛋白基因表达的结果与未转BMP7组无明显差异。有了这些结果，我们不能说明BMP7在肝硬变治疗中的有效性。